Table 4.
Sensitivity, % (95% CI) | Specificity, % (95% CI) | Positive PV, % (95% CI) | Negative PV, % (95% CI) | Positive LHR, % (95% CI) | Negative LHR, % (95% CI) | |
---|---|---|---|---|---|---|
VTE recurrence 3 months after the discontinuation of anticoagulant treatment | ||||||
Age-adjusted D-dimer (ng/mL) | 100 (61–100) | 61 (51.4–69.7) | 12.8 (6–25.2) | 100 (94.3–100) | 2.56 (2.02–3.25) | 0 |
D-dimer of >600 ng/mL | 100 (61–100) | 60 (50.4–68.7) | 12.5 (6.59–24.7) | 100 (94.3–100) | 2.5 (1.98–3.16) | 0 |
hs-CRP of >4.5 mg/L | 100 (61–100) | 69.1 (59.3–77.4) | 16.7 (7.9–31.9) | 100 (94.6–100) | 3.23 (2.4–4.35) | 0 |
D-dimer of >600 ng/mL and/or hs-CRP of >4.5 mg/L | 100 (61–100) | 50 (40.6–59.4) | 10.2 (4.7–20.5) | 100 (93.2–100) | 2 (1.65–2.42) | 0 |
Age-adjusted D-dimer and/or hs-CRP of >4.5 mg/L | 100 (61–100) | 59.1 (42.5–61.2) | 10.5 (4.9–21.1) | 100 (93.5–100) | 2.08 (1.71–2.53) | 0 |
VTE recurrence 6 months after the discontinuation of anticoagulant treatment | ||||||
Age-adjusted D-dimer (ng/mL) | 90 (59.6–98.2) | 62 (52.2–70.9) | 19.1 (10.4–32.5) | 98.4 (91.5–99.7) | 2.37 (1.71–3.28) | 0.16 (0.02–1.05) |
D-dimer of >600 ng/mL | 90 (59.6–98.2) | 61 (51.2–70) | 18.8 (10.2–31.9) | 98.4 (91.4–99.7) | 2.31 (1.67–3.18) | 0.16 (0.03–1.07) |
hs-CRP of >4.5 mg/L | 90 (59.6–98.2) | 71.7 (61.8–79.9) | 25.7 (14.2–42.1) | 98.5 (92–99.7) | 3.18 (2.17–4.68) | 0.14 (0.02–0.91) |
D-dimer of >600 ng/mL and/or hs-CRP of >4.5 mg/L | 90 (59.6–98.2) | 51.5 (41.9–61) | 15.5 (8.4–26.9) | 98.1 (90.1–99.7) | 1.86 (1.39–2.47) | 0.19 (0.03–1.27) |
Age-adjusted D-dimer and/or hs-CRP of >4.5 mg/L | 90 (59.6–98.2) | 53.5 (43.8–62.9) | 16.1 (8.7–27.8) | 98.2 (90.4–99.7) | 1.93 (1.44–2.59) | 0.19 (0.03–1.22) |
CI confidence interval, PV predictive value, LHR likelihood ratio